MIGS and Meds in Glaucoma Management: Applying Evidence to Practice

Glaucoma remains a serious threat to vision, despite various treatment options. Advances in the understanding of aqueous humor outflow mechanisms have contributed to the development of more effective techniques for the management of intraocular pressure (IOP), but controversies remain. A growing number of procedures that avoid conjunctival dissection, collectively termed minimally invasive glaucoma surgery (MIGS), offer alternatives to trabeculectomy for patients who would benefit from IOP low...
This continuing education activity is provided by Vindico Medical Education.

MIGS and Meds in Glaucoma Management: Applying Evidence to Practice

Glaucoma remains a serious threat to vision, despite various treatment options. Advances in the understanding of aqueous humor outflow mechanisms have contributed to the development of more effective techniques for the management of intraocular pressure (IOP), but controversies remain. A growing number of procedures that avoid conjunctival dissection, collectively termed minimally invasive glaucoma surgery (MIGS), offer alternatives to trabeculectomy for patients who would benefit from IOP low...
Vindico Medical Education

The Rise of New Regimens in nAMD and DME Management

The standard-of-care treatment for patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is intravitreal anti-vascular endothelial growth factor (VEGF) therapy. Although most patients receiving these therapies experience significant visual acuity gains, a proportion remain suboptimal in their response. In addition, the frequency of dosing required to maintain initial visual outcomes can be challenging to maintain, resulting in undertreatment of disea...
Vindico Medical Education

The Rise of New Regimens in nAMD and DME Management

The standard-of-care treatment for patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is intravitreal anti-vascular endothelial growth factor (VEGF) therapy. Although most patients receiving these therapies experience significant visual acuity gains, a proportion remain suboptimal in their response. In addition, the frequency of dosing required to maintain initial visual outcomes can be challenging to maintain, resulting in undertreatment of disea...
Vindico Medical Education

The Promise of Nerve Growth Factor Therapy: Managing Neurotrophic Keratitis and Beyond

The early diagnosis and management of neurotrophic keratitis (NK) is imperative to avoid complications such as ulceration, infection, stromal melting, perforation secondary to poor healing, and vision loss. Diagnosis of the early stages of NK can be challenging because patients typically experience few symptoms, which leads to delays in management initiation and the potential for epithelial damage. Current and emerging treatment options―when integrated optimally into management protocols―r...
Vindico Medical Education

Improving Ocular Surface and Eyelid Health in Today’s Environment

Ocular surface diseases (OSD) are highly prevalent but frequently underdiagnosed and undertreated disorders of the cornea, conjunctiva, and meibomian glands. The spectrum of OSD includes dry eye disease, blepharitis, and meibomian gland dysfunction. These disorders can significantly affect patients’ quality of life, work, and daily activities, and also contribute to suboptimal outcomes from ocular surgery. As our understanding of the risk factors and underlying mechanisms of these conditions...
Vindico Medical Education

Improving Ocular Surface and Eyelid Health in Today’s Environment

Ocular surface diseases (OSD) are highly prevalent but frequently underdiagnosed and undertreated disorders of the cornea, conjunctiva, and meibomian glands. The spectrum of OSD includes dry eye disease, blepharitis, and meibomian gland dysfunction. These disorders can significantly affect patients’ quality of life, work, and daily activities, and also contribute to suboptimal outcomes from ocular surgery. As our understanding of the risk factors and underlying mechanisms of these conditions...
Vindico Medical Education

Highlights From Thyroid Eye Disease Forum: Drilling Down and Digging Deeper to Ensure Early Diagnosis and Treatment

Thyroid eye disease (TED) is an autoimmune disorder believed to result from the stimulation of several receptors located in the orbital fibroblasts. It is frequently misdiagnosed, due to both its heterogeneous clinical presentation and a failure on the part of clinicians to understand the relationship between TED and hyperthyroidism. Misdiagnosis can place patients at risk, as management of TED is most effective during the initial, active phase of the disease. However, differential diagnosis c...
Vindico Medical Education

“Seeing” Eye Drops Expand the Therapeutic Landscape for Presbyopia

Presbyopia is a universal phenomenon accompanying the aging process. Treatment options for presbyopia are currently limited to corrective lenses or invasive surgical procedures that may not be reversible. Patients who require or desire independence from corrective lenses have limited alternatives. However, a pharmacological alternative"pilocarpine HCl ophthalmic solution 1.25%"was recently approved by the FDA, and several more agents for presbyopia are in development, including CSF-1...
Vindico Medical Education

Tools & Techniques to Enhance Surgical Efficacy & Efficiency

This series of six webcasts offers insight on various issues that are important to eye care professionals. Each of the webcasts features individualized content, including how to run an efficient practice while caring for patients in the COVID-19 era; use of high-quality screening, monitoring and imaging devices across eye care subspecialties; thorough discussions on why connectivity and transfer of preoperative data to intraoperative technology is necessary for optimal visual outcomes; and the...
Evolve Medical Education LLC

Tools & Techniques to Enhance Surgical Efficacy & Efficiency

This series of six webcasts offers insight on various issues that are important to eye care professionals. Each of the webcasts features individualized content, including how to run an efficient practice while caring for patients in the COVID-19 era; use of high-quality screening, monitoring and imaging devices across eye care subspecialties; thorough discussions on why connectivity and transfer of preoperative data to intraoperative technology is necessary for optimal visual outcomes; and the...
Evolve Medical Education LLC

Chronic Versus Acute: Rethinking Dry Eye Disease

This continuing education activity (CE) captures content from a virtual roundtable discussion. ACTIVITY DESCRIPTION Dry eye disease (DED) is a significant public health issue that threatens patient economic productivity and quality of life. About 16 million Americans have a formal DED diagnosis, but the true incidence is likely much higher because many who are symptomatic may not seek medical care. This supplement addresses this issue and others related to managing DED and providing the ...
Evolve Medical Education LLC

Neuromyelitis Optica Spectrum Disorder: Management Updates and Challenging Clinical Cases

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. NMOSD is often misdiagnosed in the early stages, but the integration of newer diagnostic criteria may assist in an earlier and more accurate differential diagnosis. Until recently, treatment options for NMOSD have been limited―but several approved biologic thera...
Vindico Medical Education

Neuromyelitis Optica Spectrum Disorder: Management Updates and Challenging Clinical Cases

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease of the central nervous system that mainly manifests through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. NMOSD is often misdiagnosed in the early stages, but the integration of newer diagnostic criteria may assist in an earlier and more accurate differential diagnosis. Until recently, treatment options for NMOSD have been limited―but several approved biologic thera...
Vindico Medical Education

Ocular Surface Health and Surgical Outcomes

Nearly 33% of patients in eye care clinics present with com­plaints about dry eye signs and symptoms. Clinicians remain challenged with both the diagnosis and best treatment options for dry eye disease (DED) because, to date, multiple causes of the disorder have been identified. This activity will help to inform cli­nicians on methods to improve the care of patients with DED.
Evolve Medical Education LLC

OSD: Improving Patient Outcomes Through Collaborative Care

Nearly 33% of patients in eye care clinics present with com­plaints about dry eye signs and symptoms. Clinicians remain challenged with both the diagnosis and best treatment options for dry eye disease (DED) because, to date, multiple causes of the disorder have been identified. This activity will help to inform cli­nicians on methods to improve the care of patients with DED.
Evolve Medical Education LLC

Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma

Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local...
Vindico Medical Education

Tracking and Treating Uveitic Macular Edema: A Difficult Dilemma

Uveitic macular edema (UME) has a wide variety of causes. If not appropriately treated, it eventually causes damage to the photoreceptors in the macula, resulting in vision-threatening complications like macular ischemia or macular hole formation. Corticosteroids are the first-line treatment for uveitic inflammation and UME. However, they are not generally considered to be appropriate for long-term treatment due to adverse effects, including increased intraocular pressure and cataract in local...
Vindico Medical Education

Diabetic Macular Edema: Employing Inflammatory Markers to Predict Improved Visual Outcomes

Real-world outcomes with intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with diabetic macular edema (DME) do not always replicate those seen in clinical studies. In part, these discrepancies are due to treatment burden, lack of adherence, undertreatment, and incomplete response to anti-VEGF therapies. The identification of several inflammatory cytokines in the aqueous and vitreous humor whose concentrations correlate closely with the severity o...
Vindico Medical Education

Diabetic Macular Edema: Employing Inflammatory Markers to Predict Improved Visual Outcomes

Real-world outcomes with intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with diabetic macular edema (DME) do not always replicate those seen in clinical studies. In part, these discrepancies are due to treatment burden, lack of adherence, undertreatment, and incomplete response to anti-VEGF therapies. The identification of several inflammatory cytokines in the aqueous and vitreous humor whose concentrations correlate closely with the severity o...
Vindico Medical Education

nAMD and DME Management: Rapid Response From ARVO

Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing...
This continuing education activity is provided by Vindico Medical Education.

nAMD and DME Management: Rapid Response From ARVO

Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing...
This continuing education activity is provided by Vindico Medical Education.

Geographic Atrophy: Rapid Response from ARVO

Geographic atrophy (GA) is a pathological deterioration of the retina seen in the late stages of age-related macular degeneration (AMD). It affects 20% of people with AMD, and its prevalence increases exponentially with age. Until recently, there were no treatment options for GA, but investigation into the complement system and its role in the pathogenesis of GA has led to targeted therapies that have revolutionized the treatment paradigm. Because of the recent approval of one of these therapi...
This continuing education activity is provided by Vindico Medical Education.

A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack

Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinic...
This continuing education activity is provided by Vindico Medical Education.

Eyeing the Options for Treating Meibomian Gland Dysfunction and Dry Eye Disease

Dry eye disease (DED) is highly prevalent but frequently underdiagnosed and subsequently undertreated. Studies have demonstrated that meibomian gland dysfunction (MGD) is a leading cause of the development and progression of evaporative DED, caused by a deficient tear film lipid layer that leads to increased tear evaporation. New and emerging treatments with novel mechanisms of action are being investigated that manage the signs and symptoms of DED associated with MGD and offer the potential f...
This continuing education activity is provided by Vindico Medical Education.

Case Challenges in nAMD and DME Management: Achieving Durable Response

The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni...
This continuing education activity is provided by Vindico Medical Education.

Meeting Milestones in nAMD and DME Management: What's New?

Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches hav...
This continuing education activity is provided by Vindico Medical Education.

Ace the Case: An 84-Year-Old Man With Neovascular Age-Related Macular Degeneration Receiving Bilateral Every 8-Week Anti-Vascular Endothelial Growth Factor Injections

In this clinical case review, Dr. Emmanuel Chang explores options to extend treatment intervals in a patient with stable nAMD who is receiving anti-VEGF therapy every 8 weeks.
This continuing education activity is provided by Vindico Medical Education.

Ace the Case: A 65-Year-Old Woman With Chronic Diabetic Macular Edema in Both Eyes

In this clinical case review, Dr. Sara Haug explores considerations for the management of a patient with DME who is receiving monthly anti-VEGF therapy without attaining disease control.
This continuing education activity is provided by Vindico Medical Education.

Ace the Case: A 76-Year-Old Male With Active Neovascular Age-Related Macular Degeneration

In this clinical case review, Dr. Arshad Khanani explores options for switching treatment in a patient with nAMD who has become nonresponsive to anti-vascular endothelial growth factor (VEGF) therapy.
This continuing education activity is provided by Vindico Medical Education.

Secrets of Egypt & the Nile: Joint Medical/Dental Symposium Confronting Healthcare Needs

Uncover Egypt’s ancient secrets with PES for 11 nights on this bucket list adventure! Visit iconic landmarks, temples, and monuments and cruise the Nile in a manner once reserved for pharaohs aboard the luxurious, 72-guest AmaDahlia. Joint Medical/Dental Symposium Confronting Healthcare Needs CME/CE Lecture Seminars for Medical, Dental, Nursing, and Allied Healthcare Professionals This Seminar is planned for 14 Continuing Education Credit Hours. CME/CE Professional Seminar Fee:...
Professional Education Society

Recognition and Referral: Best Practices for Managing Patients with GA

Patients with advanced dry age-related macular degeneration can present with geographic atrophy (GA), a disease that is progressive and increases with age. Although there is no treatment approved by the FDA that halts or reverses GA, a number of drugs in the pipeline are designed to address GA progression, hoping to succeed where previous drug candidates failed. This series of regional, interactive, virtual symposia are designed to educate eye care providers on the importance of diagnosis and ...
Evolve Medical Education LLC

Putting Patients First: Best Practices for Neurotrophic Keratitis Diagnosis and Treatment

This previously recorded satellite symposium features an engaging presentation on the potential causes of neurotrophic keratitis, how to differentiate it from similar diseases, and when referrals may be necessary. Treatment options will also be discussed, including the mechanisms of action of newer therapies and when they should be introduced. Case discussions and audience question-and-answer session were also recorded.
Evolve Medical Education LLC

Individualizing Glaucoma Treatment: Understanding How to Utilize Traditional and Novel Agents

Join Nathan M. Radcliffe, MD, and Justin Schweitzer, OD, FAAO, as they discuss the ways in which novel therapeutics may help to overcome the challenges and limitations associated with currently available pharmacologic treatment options for ocular hypertension and primary open-angle glaucoma.
Evolve Medical Education LLC

Neurotrophic Keratitis: Old Problem, New Solutions

Eye care providers may not understand what neurotrophic keratitis is or how it differs from other corneal diseases. In addition; eye care practitioners may be unaware of treatments in development, or the already approved treatments for neurotrophic keratitis. They also may not understand the mechanism of action of these newer treatments.
Evolve Medical Education LLC

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map